Literature DB >> 24583161

Abiraterone--what is wrong with the adrenal glands?

Sabine Schmid1, Jürgen Fornaro2, Christian Rothermundt3, Aurelius Omlin3, Michael Brändle4, Niels J Rupp5, Silke Gillessen3.   

Abstract

Entities:  

Keywords:  Abiraterone acetate; Adrenal gland metastases; Metastatic castration-resistant prostate cancer; Steroid switch; Visceral disease

Mesh：

Substances：

Year:  2014        PMID： 24583161     DOI： 10.1016/j.clgc.2014.01.008

Source DB:  PubMed          Journal:  Clin Genitourin Cancer        ISSN： 1558-7673            Impact factor:   2.872


× No keyword cloud information.
  2 in total

Review 1.  Switching and withdrawing hormonal agents for castration-resistant prostate cancer.

Authors:  David Lorente; Joaquin Mateo; Zafeiris Zafeiriou; Alan D Smith; Shahneen Sandhu; Roberta Ferraldeschi; Johann S de Bono
Journal:  Nat Rev Urol       Date:  2015-01       Impact factor: 14.432

2.  PSA response following the 'steroid switch' in patients with castration-resistant prostate cancer treated with abiraterone: A case report.

Authors:  Tomonori Kato; Satoko Kojima; Ayumi Fujimoto; Kotaro Otsuka; Takahito Suyama; Kyokushin Hou; Kazuhiro Araki; Hiroshi Masuda; Kazuto Yamazaki; Akira Komiya; Yukio Naya
Journal:  Oncol Lett       Date:  2018-08-17       Impact factor: 2.967
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.